Directors
Geoff was part of the team that developed the first humanized antibody at the Universities of Cambridge and Oxford. Founded an academic GMP biologics manufacturing facility taking >25 antibodies to the clinic. Geoff acts as an expert in patent cases and is Director for the following companies: Mabsolve, Native Antigen Company (acquired 2020), Absolute Antibody (acquired 2020) and BioAnaLab (acquired 2009). An inventor on numerous patents he acts as an expert in patent legal disputes. Geoff is a Founder, Chairman and inventor of Bioarchitech’s oncolytic virus payloads.
Managing Director
Geoff Hale
Kevin Maskell
Kevin has over 20 years translational immunology and oncology experience. Starting at the University of Oxford developing cancer vaccines. Kevin joined Oxford spin-out company BioAnaLab, a CRO acquired by Merck KGga, providing GLP, GMP and GCP analytical services. Kevin went on to establish a biomarker laboratory in Shanghai for Merck KGga. Joined Oxford spin-out Oxford Cancer Biomarkers developing stratification tests to improve clinical oncology decision making. Kevin is Scientific Advisor to RNA company OligoTune and inventor of Bioarchitech’s immunotherapy pipeline.
CEO & CSO
Operations
Andri is a molecular virologist with more than 10 years experience of RNA viruses and immunology. As a Research Fellow at the University of St Andrews she was awarded the Wellcome Trust Institutional Strategic Support Fund to investigate the therapeutic applications of defective viral genomes of paramyxoviruses. Her post-doctoral research revealed a novel function for interferon (IFN)-stimulated gene ISG15. During her PhD she developed a screening platform identifying inhibitors of respiratory syncytial virus. At Bioarchitech, Andri is the inventor of Bioarchitech’s RNA products.
Head of Platform Development
Andri Vasou
William Jackson
William has over 10 years of experience in immunology, oncology and cardiovascular disease. During his 6 years of post-doctoral research at Imperial College London, he specialised in the innate immune system in the context of cancer and autoimmunity. William has considerable experience of pre-clinical disease models and a passion for excellence within in vivo research. At Bioarchitech, William is inventor of Bioarchitech’s oncolytic virus payloads.
Head of Preclinical Development
Ines Loureiro
Ines graduated in 2021 with a first class honours degree in Neuroscience. During her degree Ines partook in a one-year placement at the University of Cambridge researching Rett syndrome under the lab of Prof Ole Paulsen. Ines worked two years at Oxford Biomedica, a gene therapy company, gaining valuable cell culture experience. Ines is expanding her immunotherapy model expertise at Bioarchitech helping to validate our immunotherapy candidates.
Preclinical scientist
Advisors
David Kerr
David Kerr is Professor of Cancer Medicine at the University of Oxford and a Clinical Oncologist. He holds numerous awards, including the NHS Nye Bevan Award for Innovation, the China Friendship Medal, and a CBE for contributions to cancer research. He has published over 300 scientific papers, authored 20+ books, holds several patents, and founded two biotech companies. He is also a former President of the European Society of Medical Oncology.
Oncology Advisor
Lily Wang
Lili has over 20 years of translational experience in cancer immunotherapy and infectious disease. Currently, Principal Scientist in translational immunology at Singula Bio responsible for building and implementing their cellular immunology pipeline. Lili also worked at Adaptimmune Therapeutics improving adoptive T cell immunotherapy. Lili spent 10 years at the University of Oxford where her research focused on T cell responses to infectious diseases from fundamental research to clinical studies. Lili is a Founder of Bioarchitech.
Scientific Advisor & Co-founder
Hannah Chen
Hannah has over 10 years’ experience including a strong background in oncolytic virotherapy, cancer biology, T cell immunology and Inflammatory Bowel Disease, publishing several high impact studies. She is currently a co-investigator on several research grants at the University of Oxford. Hannah has extensive industry engagement experience, having previously held the prestigious Oxford-Celgene Fellowship and currently works developing therapeutic monoclonal antibodies to autoimmune diseases. Hannah is a Founder of Bioarchitech.
Scientific Advisor & Co-founder